- Home
- VINP vs PHAR Comparison
VINP vs PHAR Comparison
Compare VINP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- PHAR
- Stock Information
- Founded
- VINP 2009
- PHAR 1988
- Country
- VINP Brazil
- PHAR Netherlands
- Employees
- VINP N/A
- PHAR N/A
- Industry
- VINP Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- PHAR Health Care
- Exchange
- VINP Nasdaq
- PHAR Nasdaq
- Market Cap
- VINP 593.2M
- PHAR 718.1M
- IPO Year
- VINP 2021
- PHAR N/A
- Fundamental
- Price
- VINP $9.51
- PHAR $11.00
- Analyst Decision
- VINP Strong Buy
- PHAR Strong Buy
- Analyst Count
- VINP 2
- PHAR 3
- Target Price
- VINP $13.25
- PHAR $30.00
- AVG Volume (30 Days)
- VINP 47.4K
- PHAR 3.0K
- Earning Date
- VINP 08-06-2025
- PHAR 07-31-2025
- Dividend Yield
- VINP 6.75%
- PHAR N/A
- EPS Growth
- VINP N/A
- PHAR N/A
- EPS
- VINP 0.38
- PHAR N/A
- Revenue
- VINP $126,696,258.00
- PHAR $320,708,000.00
- Revenue This Year
- VINP $70.28
- PHAR $13.31
- Revenue Next Year
- VINP $14.37
- PHAR $7.68
- P/E Ratio
- VINP $25.30
- PHAR N/A
- Revenue Growth
- VINP 57.51
- PHAR 24.13
- 52 Week Low
- VINP $8.66
- PHAR $6.65
- 52 Week High
- VINP $11.62
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- VINP 47.61
- PHAR 51.11
- Support Level
- VINP $9.41
- PHAR $10.23
- Resistance Level
- VINP $9.70
- PHAR $11.21
- Average True Range (ATR)
- VINP 0.23
- PHAR 0.27
- MACD
- VINP 0.01
- PHAR -0.14
- Stochastic Oscillator
- VINP 43.48
- PHAR 34.01
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.